Comparative Pharmacology
Head-to-head clinical analysis: BACTROBAN versus CLINDETS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTROBAN versus CLINDETS.
BACTROBAN vs CLINDETS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It also acts as a competitive inhibitor of bacterial ribosomal RNA methyltransferases.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Clindamycin: 150-450 mg orally every 6 hours; 600-900 mg IV every 8 hours. Max: 1.8 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Terminal elimination half-life is 2.4-3 hours in adults; prolonged to 4-6 hours in severe hepatic impairment.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Approximately 10% of the dose is excreted unchanged in urine; the remainder is hepatically metabolized and eliminated via bile (fecal: ~40%) and urine as inactive metabolites.
Category C
Category C
Topical Antibiotic
Topical Antibiotic